01—Abstract
Summary
Summary of the 8-K filed May 20, 2024. Cited figures are marked; the original filing is the authoritative source.
On May 20, 2024, Johnson & Johnson completed public debt offerings totaling approximately $4.0 billiona in U.S. dollar notes and €2.5 billion in euro notes, issued under its existing Form S-3 shelf registration (Reg.
No. 333-269836). The U.S. dollar tranches comprise four series: $1.15 billionb of 4.800% notes due 2029, $1.15 billion of 4.900% notes due 2031, $850 million of 4.950% notes due 2034, and $850 million of 5.250% notes due 2054. The euro tranches comprise €700 million of 3.200% notes due 2032, €800 million of 3.350% notes due 2036, and €1.0 billion of 3.550% notes due 2044.
The filing is largely administrative. It records the completion of previously announced offerings, identifies the underwriting agreements (U.S. dollar notes dated May 13, 2024, with J.P. Morgan, BofA Securities, and Citigroup as representatives; euro notes dated May 14, 2024, with J.P.
Morgan, Citigroup, and Deutsche Bank), and lists the exhibits, including the indenture-related company orders, note forms, and legal opinions from Weil, Gotshal & Manges and Troutman Pepper Hamilton Sanders. The filing does not disclose the intended use of proceeds, any covenants beyond those in the standard provisions, or any changes to the company's financial outlook. For investors, the key takeaways are that Johnson & Johnson raised substantial new long-term capital across two currencies and a range of maturities from five to thirty years, and that the coupon levels reflect the prevailing rate environment at the time of issuance.
The issuance adds meaningfully to the company's debt stack and extends its maturity profile. Investors should review the company's subsequent financial disclosures for how the proceeds are deployed and how the additional debt affects leverage and interest expense.
02—Key points
Key Highlights
- Completed approximately $4.0 billion in U.S. dollar notes across four tranches: $1.15B 4.800% due 2029, $1.15B 4.900% due 2031, $850M 4.950% due 2034, and $850M 5.250% due 2054.
- Completed €2.5 billion in euro notes across three tranches: €700M 3.200% due 2032, €800M 3.350% due 2036, and €1.0B 3.550% due 2044.
- Offerings were registered under the company's existing Form S-3 shelf registration (Reg. No. 333-269836), so no new registration statement was needed.
- Maturities range from 5 to 30 years, with the longest U.S. dollar tranche (5.250% due 2054) being a 30-year note.
- U.S. dollar notes were underwritten under an agreement dated May 13, 2024, led by J.P. Morgan, BofA Securities, and Citigroup; euro notes were underwritten under an agreement dated May 14, 2024, led by J.P. Morgan, Citigroup, and Deutsche Bank.
- The filing is administrative in nature and does not disclose use of proceeds, changes to guidance, or other operating results.
- Legal opinions from Weil, Gotshal & Manges LLP and Troutman Pepper Hamilton Sanders LLP were filed as exhibits, supporting the validity of the issued notes.
03—Questions
Frequently Asked Questions
How much debt did Johnson & Johnson issue in this offering?
The company issued about $4.0 billion in U.S. dollar notes across four tranches and €2.5 billion in euro notes across three tranches. The euro amount is in euros, so the dollar equivalent depends on the exchange rate at settlement.
What are the maturities and interest rates on the notes?
U.S. dollar notes: 4.800% due 2029, 4.900% due 2031, 4.950% due 2034, and 5.250% due 2054. Euro notes: 3.200% due 2032, 3.350% due 2036, and 3.550% due 2044. The maturities span roughly 5 to 30 years.
Why would investors care about this filing?
The filing shows that Johnson & Johnson has added significant long-term debt, which affects its leverage and annual interest expense. Investors would typically look to the company's later filings for how the proceeds will be used, such as refinancing maturing debt, funding acquisitions, or general corporate purposes. This 8-K does not state the use of proceeds.
Does this filing signal any change in the company's operations or outlook?
No. The filing is limited to completing previously announced debt offerings and listing related exhibits. It contains no financial results, guidance changes, or operational updates.
04—Continue